



Pfizer Pipeline

February 28, 2012


Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of February 28, 2012.
- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot	4
Cardiovascular & Metabolic Diseases	5
Inflammation & Immunology	6
Neuroscience & Pain	7
Oncology	9
Vaccines	10
Other Areas of Focus	11
Projects Discontinued Since Last Update	12

Pfizer Pipeline Snapshot



Pfizer Pipeline – February 28, 2012

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Cardiovascular and Metabolic Diseases	Viviant	Selective Estrogen Receptor Modulator	Osteoporosis Treatment and Prevention (U.S.)	Registration
	Eliquis (apixaban)	Factor Xa Inhibitor	Stroke Prevention in Atrial Fibrillation (U.S./EU)	Registration
	apixaban	Factor Xa Inhibitor	Venous Thromboembolism Prevention (U.S.)	Phase 3
	Eliquis (apixaban)	Factor Xa Inhibitor	Venous Thromboembolism Treatment	Phase 3
	PF-04971729		Diabetes Mellitus-Type 2	Phase 2
	PF-04991532		Diabetes Mellitus-Type 2	Phase 2
	RN316 (PF-04950615)		Hypercholesterolemia, Post Acute Coronary Syndrome in Diabetics (Biologic)	Phase 2
	▶ PF-04937319		Diabetes Mellitus-Type 2	Phase 2
	CVX 096 (PF-04856883)		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	OAP-189 (PF-05212389)		Diabetes Mellitus-Type 2, Obesity (Biologic)	Phase 1
	PF-03882845		Diabetic Nephropathy	Phase 1
	PF-05231023		Diabetes Mellitus-Type 2 (Biologic)	Phase 1
	PF-05175157		Diabetes Mellitus-Type 2	Phase 1
	PF-05190457		Diabetes Mellitus-Type 2	Phase 1
	PF-04840082		Osteoporosis Treatment and Prevention (Biologic)	Phase 1



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Pfizer Pipeline – February 28, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Inflammation and Immunology	▶ tofacitinib (CP-690550)	JAK Inhibitor	Rheumatoid Arthritis (U.S./EU)	Registration
	tofacitinib (CP-690550)	JAK Inhibitor	Psoriasis (Oral)	Phase 3
	PF-04171327		Rheumatoid Arthritis	Phase 2
	SBI-087 (PF-05230895)		Rheumatoid Arthritis, *Lupus (Biologic)	Phase 2
	PF-05285401		Ulcerative Colitis (Biologic)	Phase 2
	anrukinzumab (IMA-638)		Ulcerative Colitis (Biologic)	Phase 2
	PF-00547659		Crohn's Disease (Biologic)	Phase 2
	PF-04236921		Crohn's Disease, Lupus, *Rheumatoid Arthritis (Biologic)	Phase 2
	tofacitinib (CP-690550)		Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease, Ulcerative Colitis	Phase 2
	▶ PF-06473871 (EXC 001)		Dermal Scarring	Phase 2
	▶ PD-360324		Lupus (Biologic)	Phase 1
	PF-04634817		Liver Fibrosis	Phase 1



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1

Pfizer Pipeline – February 28, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain	tafamidis meglumine	Transthyretin (TTR) Dissociation Inhibitor	Transthyretin familial amyloid polyneuropathy (U.S.)	Registration
	► Lyrica	Alpha-2 Delta Ligand	Central Neuropathic Pain due to Spinal Cord Injury (U.S.)	Registration
	Celebrex	COX-2	Chronic Pain (U.S.)	Registration
	Remoxy (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain (U.S.)	Registration
	ALO-02 Oxycodone-naltrexone core (King)	Mu-type opioid receptor (MOR-1) Agonist	Moderate to Severe Pain	Phase 3
	bapineuzumab	Beta Amyloid Inhibitor	Alzheimer's Disease (Biologic)	Phase 3
	Lyrica	Alpha-2 Delta Ligand	Peripheral Neuropathic Pain	Phase 3
	Lyrica	Alpha-2 Delta Ligand	CR (once a day dosing)	Phase 3
	tanezumab	Nerve Growth Factor Inhibitor	OA Signs and Symptoms (Biologic) (On Clinical Hold)	Phase 3
	PF-02545920		Schizophrenia	Phase 2
	Eladur (King)		Chronic Pain	Phase 2
	PF-03049423		Stroke Recovery	Phase 2
	tanezumab		Cancer Pain (Biologic)	Phase 2
	► PF-03654746		Tourette's Syndrome	Phase 2

New Molecular Entity

New Indication or Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – February 28, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Neuroscience & Pain (cont'd)	▶ PF-05089771		Acute Pain, *Chronic Pain	Phase 2
	PF-05236812 (AAB-003)		Alzheimer's Disease (Biologic)	Phase 1
	PF-04958242		Schizophrenia, Sensorineural Hearing Loss	Phase 1
	Vabicaserin (PF-05208769)		Schizophrenia	Phase 1
	PF-05212377 (SAM-760)		Alzheimer's Disease	Phase 1
	PF-04427429		Migraine (Biologic)	Phase 1
	PF-05180999		Schizophrenia	Phase 1
	PF-05297909		Alzheimer's Disease	Phase 1
	PF-04531083		Severe Chronic Pain	Phase 1

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – February 28, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology	crizotinib	c-MET-ALK Inhibitor	Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer (EU)	Registration
	axitinib	VEGF Tyrosine Kinase Inhibitor	Advanced Renal Cell Carcinoma after failure of prior systemic treatment (EU)	Registration
	bosutinib	Abl and src-family kinase inhibitor	Previously Treated Chronic Myelogenous Leukemia (U.S.), Chronic Myelogenous Leukemia (EU)	Registration
	dacomitinib (PF-00299804)	pan-HER Inhibitor	Non-Small Cell Lung Cancer	Phase 3
	Xalkori (crizotinib)	c-MET-ALK Inhibitor	ALK-Positive 1 st and 2 nd Line Non-Small Cell Lung Cancer, *Cancer	Phase 3
	Inlyta (axitinib)	VEGF Tyrosine Kinase Inhibitor	Advanced Renal Cell Carcinoma in treatment-naïve patients	Phase 3
	Sutent	Multiple Tyrosine Kinase Inhibitor	Renal Cell Carcinoma Adjuvant	Phase 3
	Torisel	FKBP-Rapamycin Associated Protein	Renal Cell Carcinoma	Phase 3
	inotuzumab ozogamicin		Aggressive Non-Hodgkin's Lymphoma (Biologic)	Phase 3
	inotuzumab ozogamicin		Indolent Non-Hodgkin's Lymphoma, *Acute Lymphocytic Leukemia (Biologic)	Phase 2
	axitinib		Liver Cancer, Thyroid Cancer	Phase 2
	dacomitinib (PF-00299804)		Cancer	Phase 2
	PD-0332991		Cancer	Phase 2
	▶ CVX 060 (PF-04856884)		Renal Cell Carcinoma, *Cancer(Biologic)	Phase 2



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1

Pfizer Pipeline – February 28, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Oncology (cont'd)	▶ PF-04691502		Endometrial Cancer, *Cancer	Phase 2
	▶ PF-05212384		Endometrial Cancer, *Cancer	Phase 2
	PF-03084014		Cancer	Phase 1
	PF-03446962		Cancer (Biologic)	Phase 1
	PD-0325901		Cancer (in combination with PF-04691502)	Phase 1
	PF-05082566		Cancer (Biologic)	Phase 1
	PF-04605412		Cancer (Biologic)	Phase 1
	PF-04449913		Cancer	Phase 1
Vaccines	ACC-001 (PF-05236806)		Alzheimer's Disease	Phase 2
	MnB rLP2086 (PF-05212366)		Adolescent Meningitis, *Infant Meningitis	Phase 2
	▶ 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510)		Staph Aureus	Phase 2

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – February 28, 2012 (cont'd)

Therapeutic Area	Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Other Areas of Focus	Taliglucerase alfa	Enzyme Replacement Therapy	Gaucher Disease (Biologic)	Registration
	Xiapex (EU)	Clostridial Collagenase for Injection	Peyronie's Disease (Biologic) (EU)	Phase 3
	Eraxis/Vfend	Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation	Aspergillosis	Phase 3
	Zithromax/chloroquine	5-OS Ribosome Inhibitor	Malaria	Phase 3
	bazedoxifene-conjugated estrogens	Tissue Selective Estrogen Complex	Menopausal Vasomotor Symptoms	Phase 3
	bosutinib		Autosomal Dominant Polycystic Kidney Disease	Phase 2
	PF-00868554 (filibuvir)		Hepatitis C Virus	Phase 2
	tofacitinib (CP-690550)		Transplant Rejection, Dry Eye	Phase 2
	PH-797804		Chronic Obstructive Pulmonary Disease	Phase 2
	PF-06460031 (GMI-1070)		Vaso-occlusive crisis associated with Sickle Cell Disease	Phase 2
	PNU-100480		Tuberculosis	Phase 2
	PF-00489791		Chronic Renal Failure	Phase 2
	RN6G (PF-04382923)		Age-Related Macular Degeneration (Biologic)	Phase 1
	PF-03715455		Chronic Obstructive Pulmonary Disease	Phase 1
	▶ PF-05280602		Hemophilia (Biologic)	Phase 1

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Projects Discontinued from Development since November 10, 2011

Compound Name	Mechanism of Action (Phase 3 through regulatory approval)	Indication	Phase
Pristiq	Serotonin Norepinephrine Reuptake Inhibitor	Vasomotor Symptoms of Menopause (U.S.)	Registration
latrepirdine (Dimebon)	MpTp Modulator	Alzheimer's Disease	Phase 3
Lyrica	Alpha-2 Delta Ligand	Epilepsy Monotherapy	Phase 3
SD-6010		Osteoarthritis	Phase 2
PF-04136309		Liver Fibrosis	Phase 2
PF-04308515		Anti-Inflammatory	Phase 1
PF-04554878		Cancer	Phase 1
PF-04427429		Vasomotor Symptoms (Biologic)	Phase 1

New Molecular Entity

New Indication or Enhancement

